title: Prolonged prostaglandin E1 infusion: histologic effects on the patent ductus arteriosus.
abstract: An infant with Ebstein's malformation of the tricuspid valve and severe pulmonic stenosis underwent a 39-day course of prostaglandin E1 infusion, and a histologic study of the ductus arteriosus was undertaken after autopsy. There were marked alterations in the ductal and juxtaductal structures following this prolonged infusion of prostaglandin E1. The internal elastic lamella of the ductus was disrupted in many areas. The media showed widespread areas of disruption with cavity formation. The adventitia adjacent to the junction of the ductus with the pulmonary artery was thickened and infiltrated with mononuclear cells. The nerve trunks in the adventitia were markedly infiltrated with mononuclear cells and showed cavitation as well as considerable surrounding edema. Mucopolysaccharides were increased throughout the ductus. These changes produced increased fragility of the ductal and juxtaductal structures, thus increasing the likelihood of spontaneous aneurysms and rupture, or of tearing or rupture at the aortic and pulmonary junctions at the time of surgical closure of the ductus. Unusual fragility of the ductus, pulmonary artery, and aorta has been observed during ligation of the ductus following prostaglandin E infusions lasting seven and ten days. Additionally, another patient who had received prostaglandin E infusion for six days demonstrated aneurysmal fullness to the ductus arteriosus at autopsy. The histologic findings and intraoperative experience in this study suggest that there may be a real danger of spontaneous or surgically related rupture of the ductus arteriosus after prolonged infusion of prostaglandins.
mesh_terms: D006328:Cardiac Catheterization; D004077:Digoxin / Q000627:therapeutic use; D004373:Ductus Arteriosus / Q000166:cytology*; D004374:Ductus Arteriosus, Patent / Q000209:etiology*; D004437:Ebstein Anomaly / Q000175:diagnosis* / Q000188:drug therapy; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007261:Infusions, Intra-Arterial / Q000379:methods*; D011247:Pregnancy; D011458:Prostaglandins E / Q000009:adverse effects*
chemical_list: D011458:Prostaglandins E; D004077:Digoxin; D005665:Furosemide